Drug intelligence / Profile preview

CPC203

Development stage: Preclinical
Lead developer: Alephoson
Modality: Small Molecules
Administration: Ophthalmic

Overview

CPC203 is a preclinical-stage small molecule therapeutic being developed by Alephoson for the treatment of retinal diseases. While the specific biological target and mechanism of action have not been publicly disclosed, the candidate is part of Alephoson's ophthalmic pipeline, which utilizes proprietary delivery technologies to address conditions of the eye. The designation "R" in company documentation typically refers to retinal indications, such as age-related macular degeneration or diabetic retinopathy.

Beyond the preview

Go deeper on CPC203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPC203.

Explore the full profile